Led Terremoto Biosciences' $108M Series C to advance selective AKT1-inhibitors in oncology and hereditary hemorrhagic telangiectasia.
Terremoto Biosciences is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease, focusing on developing groundbreaking, best-in-class precision therapies using novel covalency technologies
Terremoto Biosciences is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease, focusing on developing groundbreaking, best-in-class precision therapies using novel covalency technologies.